Phase I clinical trial of daily oral gleevac (imatinib mesylate, formerly known as ST157) and one hour weekly paclitaxel infusion as a combined regimen for advanced or metastatic solid tumors refractory to standard therapy
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2006
At a glance
- Drugs Imatinib (Primary) ; Paclitaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Mar 2006 New trial record.